Rafael (RFL) vs Verrica Pharmaceuticals (VRCA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rafael (RFL) has outperformed Verrica Pharmaceuticals (VRCA) over the past year, losing 25.8% versus a loss of 34.9%. Over five years, RFL leads with a -84.2% price change compared with -97.4% for VRCA. Rafael is the larger company by market cap ($48.0 million vs $47.1 million), about 1.0 times the size, while Verrica Pharmaceuticals is growing revenue faster (+370.2% vs -4.7%).
Verrica Pharmaceuticals converts more of its revenue into profit, with a net margin of -50.3% versus -3390.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RFL | VRCA |
|---|---|---|
| Share price | $0.9197 | $2.74 |
| Market cap | $47.99M | $47.07M |
| 1-day change | +2.19% | -5.03% |
| YTD return | -22.06% | -67.03% |
| 1-year return | -25.83% | -34.92% |
| 5-year return | -84.19% | -97.38% |
| EPS (TTM) | $-0.58 | $-2.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $874.00K | $35.58M |
| Revenue growth (YoY) | -4.69% | +370.22% |
| Net income (latest FY) | $-29.64M | $-17.89M |
| Operating margin | -3822.54% | -34.25% |
| Net margin | -3390.73% | -50.27% |
| 52-week high | $3.96 | $9.82 |
| 52-week low | $0.781 | $2.73 |
| Distance from 52-week high | -76.78% | -72.10% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +404.74% |
| Average volume | 140.84K | 68.78K |
| Shares outstanding | 51.39M | 17.18M |
| Employees | 21 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Verrica Pharmaceuticals is more profitable, keeping -50.3 cents of every revenue dollar as net income versus -3390.7 cents for Rafael.
- Verrica Pharmaceuticals grew revenue faster in its latest fiscal year (+370.22% vs -4.69%).
About Rafael
RFL stock →Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Verrica Pharmaceuticals
VRCA stock →Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
RFL vs VRCA FAQ
Which is bigger, Rafael or Verrica Pharmaceuticals?
Rafael (RFL) is larger, with a market capitalization of $47.99M compared with $47.07M for Verrica Pharmaceuticals (VRCA).
Which stock has performed better over the past year, RFL or VRCA?
RFL returned -25.83% over the past 12 months, compared with -34.92% for VRCA (price return, excluding dividends). Past performance does not predict future results.
Are Rafael and Verrica Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.